Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Автори: | Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini |
---|---|
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Interna Publishing
2017-04-01
|
Серія: | Acta Medica Indonesiana |
Предмети: | |
Онлайн доступ: | http://www.actamedindones.org/index.php/ijim/article/view/327 |
Схожі ресурси
Схожі ресурси
-
Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
за авторством: Jacqueline Mui Lan Lai, та інші
Опубліковано: (2019-01-01) -
Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
за авторством: Hui Zhu, та інші
Опубліковано: (2015-01-01) -
Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment
за авторством: Jiun-Ting Wu, та інші
Опубліковано: (2015-06-01) -
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
за авторством: Vanessa Albertina Agertt, та інші -
Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan
за авторством: EVA SARTIKA DASOPANG, та інші
Опубліковано: (2020-02-01)